<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Rx Times Pharmacy Magazine&#187; FDA</title>
	<atom:link href="http://www.rxtimes.com/tag/fda/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.rxtimes.com</link>
	<description>Pharmacy news, jobs, continuing education, community and more.</description>
	<lastBuildDate>Mon, 09 Jan 2012 03:45:59 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>FDA Accepts ELIQUIS® (apixaban) New Drug Application</title>
		<link>http://www.rxtimes.com/fda-accepts-eliquis%c2%ae-apixaban-new-drug-application-for-review-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation/</link>
		<comments>http://www.rxtimes.com/fda-accepts-eliquis%c2%ae-apixaban-new-drug-application-for-review-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation/#comments</comments>
		<pubDate>Tue, 29 Nov 2011 23:16:31 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[apixaban]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[ELIQUIS®]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Pfizer]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5646</guid>
		<description><![CDATA[Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for ELIQUIS® (apixaban), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The FDA accepted the filing and assigned [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/fda-accepts-eliquis%c2%ae-apixaban-new-drug-application-for-review-for-the-prevention-of-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>First FDA-Approved Supplemental Blood Test for Chagas Disease</title>
		<link>http://www.rxtimes.com/first-fda-approved-supplemental-blood-test-for-chagas-disease/</link>
		<comments>http://www.rxtimes.com/first-fda-approved-supplemental-blood-test-for-chagas-disease/#comments</comments>
		<pubDate>Tue, 22 Nov 2011 05:06:57 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[Abbott]]></category>
		<category><![CDATA[CDC]]></category>
		<category><![CDATA[Centers for Disease Control and Prevention]]></category>
		<category><![CDATA[Chagas Disease]]></category>
		<category><![CDATA[FDA]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5569</guid>
		<description><![CDATA[Abbott (NYSE: ABT) received approval from the U.S. Food and Drug Administration (FDA) for a new Chagas in vitro diagnostic test. The ABBOTT ESA Chagas is the first FDA-approved supplemental test that detects antibodies to Trypanosoma cruzi (T. cruzi), a parasite found only in the Americas and commonly acquired through contact with the blood-sucking triatomine, [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/first-fda-approved-supplemental-blood-test-for-chagas-disease/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Issues Grant To Research Gluten In Medications</title>
		<link>http://www.rxtimes.com/fda-issues-grant-to-research-gluten-in-medications/</link>
		<comments>http://www.rxtimes.com/fda-issues-grant-to-research-gluten-in-medications/#comments</comments>
		<pubDate>Wed, 16 Nov 2011 23:22:38 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Gluten In Medications]]></category>
		<category><![CDATA[National Foundation for Celiac Awareness (NFCA)]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5651</guid>
		<description><![CDATA[The National Foundation for Celiac Awareness (NFCA) is proud to announce that the organization has been awarded a $50,000 grant from The Food and Drug Administration (FDA) to fund the first scientific research in the area of gluten in medication. The project entitled, “Gluten in Medication: Qualifying the extent of exposure to people with celiac [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/fda-issues-grant-to-research-gluten-in-medications/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Lilly CEO Says Appropriate Assessment of Both Benefits and Risks Critical in Regulatory Process</title>
		<link>http://www.rxtimes.com/lilly-ceo-says-appropriate-assessment-of-both-benefits-and-risks-critical-in-regulatory-process/</link>
		<comments>http://www.rxtimes.com/lilly-ceo-says-appropriate-assessment-of-both-benefits-and-risks-critical-in-regulatory-process/#comments</comments>
		<pubDate>Wed, 02 Nov 2011 13:23:00 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Eli Lilly and Company]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[PDUFA]]></category>
		<category><![CDATA[Prescription Drug User Fee Act]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5520</guid>
		<description><![CDATA[To sustain medical innovation, the FDA must accelerate the adoption of a Benefit-Risk framework to inform decision-making in the regulatory process, said John Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: LLY). In an address at the FDA News Fourth Annual Risk Management and Drug Safety Summit, Lechleiter called for a [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/lilly-ceo-says-appropriate-assessment-of-both-benefits-and-risks-critical-in-regulatory-process/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent</title>
		<link>http://www.rxtimes.com/abbott-receives-u-s-fda-approval-for-next-generation-xience-primetm-drug-eluting-stent/</link>
		<comments>http://www.rxtimes.com/abbott-receives-u-s-fda-approval-for-next-generation-xience-primetm-drug-eluting-stent/#comments</comments>
		<pubDate>Wed, 02 Nov 2011 04:29:00 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Abbott]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[XIENCE PRIME(TM)]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5497</guid>
		<description><![CDATA[Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. With the introduction of XIENCE PRIME in the United States, Abbott, the worldwide leader in drug eluting stent technology, now offers physicians an [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/abbott-receives-u-s-fda-approval-for-next-generation-xience-primetm-drug-eluting-stent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>U.S. Food and Drug Administration Extends Action Date for Dapagliflozin by Three Months</title>
		<link>http://www.rxtimes.com/u-s-food-and-drug-administration-extends-action-date-for-dapagliflozin-by-three-months/</link>
		<comments>http://www.rxtimes.com/u-s-food-and-drug-administration-extends-action-date-for-dapagliflozin-by-three-months/#comments</comments>
		<pubDate>Thu, 27 Oct 2011 04:51:14 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[Dapagliflozin]]></category>
		<category><![CDATA[FDA]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5514</guid>
		<description><![CDATA[Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced today that the U.S. Food and Drug Administration (FDA) has extended the action date for dapagliflozin for the treatment of type 2 diabetes by three months. The new Prescription Drug User Fee Act (PDUFA) goal date is January 28, 2012. “Bristol-Myers Squibb and AstraZeneca are [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/u-s-food-and-drug-administration-extends-action-date-for-dapagliflozin-by-three-months/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The National Association Of Boards Of Pharmacy And Pfizer Partner To Educate Patients About The Flood Of Counterfeit Medicines Online</title>
		<link>http://www.rxtimes.com/the-national-association-of-boards-of-pharmacy-and-pfizer-partner-to-educate-patients-about-the-flood-of-counterfeit-medicines-online/</link>
		<comments>http://www.rxtimes.com/the-national-association-of-boards-of-pharmacy-and-pfizer-partner-to-educate-patients-about-the-flood-of-counterfeit-medicines-online/#comments</comments>
		<pubDate>Thu, 29 Sep 2011 13:11:40 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[Life+People]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[National Association Of Boards Of Pharmacy]]></category>
		<category><![CDATA[Online Pharmacy]]></category>
		<category><![CDATA[Pfizer]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5462</guid>
		<description><![CDATA[NEW YORK &#8211; Pfizer Inc. (NYSE: PFE) and the National Association of Boards of Pharmacy® (NABP) are launching a new effort to draw attention to the risks associated with counterfeit prescription medicines and help patients learn how to safely buy medicines online. Prescription medicines are among the most counterfeited consumer goods. Worldwide sales of counterfeit [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/the-national-association-of-boards-of-pharmacy-and-pfizer-partner-to-educate-patients-about-the-flood-of-counterfeit-medicines-online/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>New FDA-Approved Antidote for Cyanide Poisoning</title>
		<link>http://www.rxtimes.com/new-fda-approved-antidote-for-cyanide-poisoning/</link>
		<comments>http://www.rxtimes.com/new-fda-approved-antidote-for-cyanide-poisoning/#comments</comments>
		<pubDate>Thu, 18 Aug 2011 03:01:01 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Cyanide Poisoning Antidote]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Hope Pharmaceuticals]]></category>
		<category><![CDATA[Nithiodote©]]></category>
		<category><![CDATA[Sodium Nitrite Injection]]></category>
		<category><![CDATA[Sodium Thiosulfate Injection]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5444</guid>
		<description><![CDATA[Hope Pharmaceuticals today announced the launch of Nithiodote© (co-packaged Sodium Nitrite Injection, USP and Sodium Thiosulfate Injection, USP), a new antidote indicated for the treatment of acute cyanide poisoning that is judged to be life-threatening. Because the introduction of new antidotes for the treatment of chemical threats can enhance public safety and homeland security, the [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/new-fda-approved-antidote-for-cyanide-poisoning/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Abbott Receives FDA Approval for Two Three-Month Strengths of Lupron Depot-PED® for the Treatment of CPP</title>
		<link>http://www.rxtimes.com/abbott-receives-fda-approval-for-two-three-month-strengths-of-lupron-depot-ped%c2%ae-for-the-treatment-of-cpp/</link>
		<comments>http://www.rxtimes.com/abbott-receives-fda-approval-for-two-three-month-strengths-of-lupron-depot-ped%c2%ae-for-the-treatment-of-cpp/#comments</comments>
		<pubDate>Wed, 17 Aug 2011 02:52:25 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Abbott]]></category>
		<category><![CDATA[Central Precocious Puberty]]></category>
		<category><![CDATA[CPP]]></category>
		<category><![CDATA[Depot-PED®]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Leuprolide Acetate for Depot Suspension]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5442</guid>
		<description><![CDATA[ABBOTT PARK, Ill., &#8211; Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED ® (leuprolide acetate for depot suspension) for the treatment of children with central precocious puberty (CPP). CPP is a condition that causes children to enter puberty too [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/abbott-receives-fda-approval-for-two-three-month-strengths-of-lupron-depot-ped%c2%ae-for-the-treatment-of-cpp/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Advisory Committee Makes Recommendation on Investigational Compound Dapagliflozin</title>
		<link>http://www.rxtimes.com/fda-advisory-committee-makes-recommendation-on-investigational-compound-dapagliflozin/</link>
		<comments>http://www.rxtimes.com/fda-advisory-committee-makes-recommendation-on-investigational-compound-dapagliflozin/#comments</comments>
		<pubDate>Thu, 21 Jul 2011 12:25:08 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[Dapagliflozin]]></category>
		<category><![CDATA[FDA]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5341</guid>
		<description><![CDATA[PRINCETON, N.J. &#038; WILMINGTON, Del. &#8211; Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today reported the outcome of the U.S. Food and Drug Administration&#8217;s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on the New Drug Application for the investigational compound dapagliflozin. “Do the efficacy and safety data provide substantial evidence to support [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/fda-advisory-committee-makes-recommendation-on-investigational-compound-dapagliflozin/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

